Saposin Delivery to Dendritic Cells for Tumor Antigen Presentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Antigen presentation and T cell activation in the tumor microenvironment are often suppressed, facilitating immune escape and precluding effective cancer therapy.
Innovation Solution
Enhancing antigen presentation by increasing the expression or levels of saposins in the tumor microenvironment, particularly through compositions comprising saposin or prosaposin targeted for delivery to dendritic cells, optionally chemically conjugated with an antigen binding moiety like an antibody, and targeting dendritic cells via DEC205.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If saposin levels are increased in the tumor microenvironment, then antigen presentation by dendritic cells is enhanced, but the complexity of delivering saposin specifically to dendritic cells increases
Solution Approach 1:
The patent uses dendritic cell-targeting moieties as intermediaries to deliver saposin specifically to dendritic cells. These targeting moieties act as mediators that bridge the saposin cargo and the dendritic cell receptors, enabling selective delivery without complex systemic delivery systems. The targeting moiety binds to surface receptors on dendritic cells, facilitating specific uptake of the saposin cargo into the endolysosomal compartment where it can exert its antigen-presenting effects.
2Reliability
If saposin is delivered to dendritic cells to enhance anti-tumor immunity, then T cell activation is improved, but the difficulty of detecting and measuring saposin delivery and efficacy increases
Solution Approach 1:
The patent incorporates fluorescently labeled saposin or fluorescently labeled targeting moieties to enable visual detection and tracking of saposin delivery to dendritic cells. The fluorescent labels act as optical markers that allow researchers to monitor delivery efficiency, cellular uptake, and localization using fluorescence microscopy and flow cytometry. This optical tagging approach converts the invisible biochemical process into a detectable optical signal.
3Stability of the object's composition
If prosaposin is used instead of saposin, then the composition can be more stable, but the manufacturing precision required to process prosaposin into active saposin increases
Solution Approach 1:
The patent delivers prosaposin (the precursor form) to dendritic cells, where it is then processed into active saposin within the cell. This preliminary delivery of the stable precursor form avoids the need for precise external proteolytic processing. The dendritic cell's endogenous proteolytic machinery performs the conversion from prosaposin to saposin in the appropriate intracellular compartment, ensuring proper activation without requiring complex external processing steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly enhances anti-tumor immunity, reducing tumor volume by at least 20% and increasing anti-tumor immunity by at least 10%, as assessed by T lymphocyte stimulation.
Implementation Method 1
the saposin or prosaposin degrades apoptotic vesicles from the tumor
Implementation Method 2
the saposin or prosaposin comprises an antigen binding moiety that binds a dendritic cell antigen
Data Source
AI summary
Provided herein are compositions and methods for the delivery of prosaposin and saposins within the tumor microenvironment in order to enhance anti-tumor immunity.